Emerging Treatments for Psoriasis: What Do Interleukin-17 Antagonists Promise?


  • Burhan Engin
  • Muazzez Çiğdem Oba
  • Zekayi Kutlubay
  • Server Serdaroğlu

J Turk Acad Dermatol 2018;12(3):0-0


IL-17 antagonists are a new class of biologic agents consisting of antibodies against IL-17A and its receptor. Three biologic agents belong to this novel category: Secukinumab, ixekizumab and brodalumab. These new agents are highly effective for treatment of moderate to severe psoriasis leading to complete or almost complete clearance of psoriatic lesions in a substantial proportion of patients. Results reported on the safety of IL-17 antagonists are also promising.

Keywords: Biologic agents, interleukin-17 antagonists, secukinumab, ixekizumab, brodalumab, psoriasis